active folate

PreclinicalSmall molecule

SShanghai Changzheng Hospital

active folate is one of 35 small molecule programs targeting Type 1 Diabetes. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 1 DiabetesActive, not recruiting

Type 1 DiabetesPreclinical

Active, not recruiting

Competition

Competitive Landscape

77 competitors in Type 1 Diabetes

#DrugCompanyPhaseTrials

Mounjaro

Eli Lilly

Approved

6 2

Symlin

AstraZeneca

Approved

4 3

Alka-Seltzer

AAbbott

Approved

1 4

Ozempic

Novo Nordisk

Phase 3

7 5

Singulair

Stelara

1 7

Inpefa

LLexicon Pharmaceuticals

Phase 3

5 8

Tricor

JJagotec

Phase 3

2 9

Atorvastatin Calcium

Merck & Co.

Phase 3

1 10

Diamox

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

N/ANot yet recruiting

Type 1 Diabetes

NCT06930144

Clinical

Trials by Indication[1]

Type 1 Diabetes1 trial

5-MTHF Supplementation for Treatment of Type 1 Diabetes Patients

Not yet recruiting·SShanghai Changzheng Hospital·N/A·NCT06930144·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for active folate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — active folate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for active folate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Changzheng Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShanghai Changzheng Hospital

active folate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Type 1 Diabetes1 trial

References

Drug Info

Quick Facts

Related News